645 related articles for article (PubMed ID: 16421906)
1. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
[TBL] [Abstract][Full Text] [Related]
2. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
3. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.
Cheung NK; Cheung IY; Canete A; Yeh SJ; Kushner B; Bonilla MA; Heller G; Larson SM
Cancer Res; 1994 Apr; 54(8):2228-33. PubMed ID: 8174131
[TBL] [Abstract][Full Text] [Related]
4. Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma.
Cheung NK; Guo HF; Heller G; Cheung IY
Clin Cancer Res; 2000 Jul; 6(7):2653-60. PubMed ID: 10914706
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience.
Kushner BH; Kramer K; LaQuaglia MP; Modak S; Cheung NK
Med Pediatr Oncol; 2003 Dec; 41(6):508-15. PubMed ID: 14595707
[TBL] [Abstract][Full Text] [Related]
6. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F
Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767
[TBL] [Abstract][Full Text] [Related]
7. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
8. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors.
Chan KW; Petropoulos D; Choroszy M; Herzog C; Jaffe N; Ater J; Korbling M
Bone Marrow Transplant; 1997 Dec; 20(12):1039-43. PubMed ID: 9466276
[TBL] [Abstract][Full Text] [Related]
9. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
Al-Faris N; Al Harbi T; Goia C; Pappo A; Doyle J; Gassas A
Pediatr Blood Cancer; 2007 Aug; 49(2):190-5. PubMed ID: 17262797
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
[TBL] [Abstract][Full Text] [Related]
11. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
[TBL] [Abstract][Full Text] [Related]
12. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
[TBL] [Abstract][Full Text] [Related]
13. Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma.
Bhandari S; Cheung NK; Kushner BH; Kramer K; Modak S; Larson SM; Yeh S; Heller G; Sklar CA
Pediatr Blood Cancer; 2010 Jul; 55(1):76-80. PubMed ID: 20213847
[TBL] [Abstract][Full Text] [Related]
14. Growth in children with poor-risk neuroblastoma after regimens with or without total body irradiation in preparation for autologous bone marrow transplantation.
Hovi L; Saarinen-Pihkala UM; Vettenranta K; Lipsanen M; Tapanainen P
Bone Marrow Transplant; 1999 Nov; 24(10):1131-6. PubMed ID: 10578163
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
[TBL] [Abstract][Full Text] [Related]
16. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma.
Kushner BH; Kramer K; Modak S; Qin LX; Cheung NK
Cancer; 2010 Jun; 116(12):3054-60. PubMed ID: 20564411
[TBL] [Abstract][Full Text] [Related]
17. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
[TBL] [Abstract][Full Text] [Related]
20. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
